Antipsychotic use by medicaid-insured youths: impact of eligibility and psychiatric diagnosis across a decade.
暂无分享,去创建一个
L. Magder | D. Safer | J. Zito | M. Burcu | Aloysius Ibe
[1] G. Carlson,et al. Diagnostic implications of informant disagreement for manic symptoms. , 2011, Journal of child and adolescent psychopharmacology.
[2] Marie A. McPherson,et al. Early diagnoses and psychotherapeutic medication treatment experiences of a cohort of children under 6 years old who received antipsychotic treatment in Florida's Medicaid program. , 2011, Journal of child and adolescent psychopharmacology.
[3] Ellen Leibenluft,et al. Severe mood dysregulation, irritability, and the diagnostic boundaries of bipolar disorder in youths. , 2011, The American journal of psychiatry.
[4] M. Helm,et al. Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005. , 2010, Psychiatric services.
[5] Barbara Napolitano,et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. , 2009, JAMA.
[6] M. Olfson,et al. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. , 2009, Health affairs.
[7] M. Olfson,et al. Mental health treatment received by youths in the year before and after a new diagnosis of bipolar disorder. , 2009, Psychiatric services.
[8] S. Kuperman,et al. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. , 2009, Journal of child and adolescent psychopharmacology.
[9] M. Swartz,et al. Who are the new users of antipsychotic medications? , 2008, Psychiatric services.
[10] Carmen Moreno,et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. , 2006, Archives of general psychiatry.
[11] P. Jensen,et al. Pharmacotherapy of aggression in children and adolescents: efficacy and effect size. , 2006, Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent.
[12] E. Youngstrom,et al. Bipolar Diagnoses in Community Mental Health: Achenbach Child Behavior Checklist Profiles and Patterns of Comorbidity , 2005, Biological Psychiatry.
[13] M. Crismon,et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.
[14] K. Schulman,et al. Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States. , 2005, Archives of pediatrics & adolescent medicine.
[15] K. Soeken,et al. Effect of Medicaid eligibility category on racial disparities in the use of psychotropic medications among youths. , 2005, Psychiatric services.
[16] D. Safer. A Comparison of Risperidone-Induced Weight Gain Across the Age Span , 2004, Journal of clinical psychopharmacology.
[17] L. Magder,et al. Psychotropic practice patterns for youth. , 2003 .
[18] F. Lynch,et al. Trends in the prescribing of psychotropic medications to preschoolers. , 2000, JAMA.
[19] M. Williams,et al. Prepubertal and young adolescent bipolarity versus ADHD: assessment and validity using the WASH-U-KSADS, CBCL and TRF. , 1998, Journal of affective disorders.
[20] M. Olfson,et al. Trends in antipsychotic drug use by very young, privately insured children. , 2010, Journal of the American Academy of Child and Adolescent Psychiatry.